Today: 29 April 2026
Browse Category

NASDAQ:EWTX 18 December 2025 - 30 December 2025

Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics shares rose 0.2% to $24.68 after a Form 144 filing showed officer Robert Michael Carruthers sold 116,665 shares for about $3.04 million on Dec. 26. The stock traded between $24.40 and $24.92 midday. The sale followed a Dec. 24 update on the company’s Phase 2 trial of EDG-7500 in hypertrophic cardiomyopathy. Biotech stocks broadly traded lower.
30 December 2025
·
Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

Edgewise Therapeutics shares fell 4.7% to around $26.00 Friday after a clinical update on its EDG-7500 program in hypertrophic cardiomyopathy. The company reported no significant safety concerns in interim Phase 2 data, with over 40 participants enrolled and no clinically meaningful drops in ejection fraction. Biotech stocks lagged, with XBI down 1.16% and IBB off 0.86%, while broader indexes traded flat.
26 December 2025
·
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics shares closed at $27.38 on December 24, up 26% after the company reported a favorable interim safety update for its EDG-7500 therapy in hypertrophic cardiomyopathy. Pre-market trading showed the stock at $27.46 as of 8:52 a.m. ET Friday. No clinically meaningful drops in ejection fraction or new atrial fibrillation were seen in the latest trial cohort. Regular U.S. trading resumes at 9:30 a.m. ET.
26 December 2025
···
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics shares jumped 21% to $26.37 intraday Wednesday after the company reported positive interim safety data for its EDG-7500 therapy in hypertrophic cardiomyopathy. The update showed no clinically meaningful LVEF reductions and no LVEF drops below 50% among 20 patients, with one new-onset atrial fibrillation event disclosed. Over 40 participants have enrolled in Part D of the trial.
24 December 2025
··
Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

Edgewise Therapeutics shares swung between $27.77 and $21.18 on Dec. 22, closing at $21.29 with volume over one million. The volatility followed a 20.8% surge on Dec. 19 and mixed analyst commentary, including JPMorgan raising its price target to $34 despite concerns over a $40.67 million quarterly loss.
22 December 2025
··
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics shares surged 20.8% to $25.55 on December 19, 2025, trading over 3.1 million shares after a prior decline. No new company press releases or major updates were issued in the past 24–48 hours. The move followed routine equity grant news on December 2 and Q3 results on November 6. Analyst price targets remain above current levels.
21 December 2025
··
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics shares surged 20.8% to $25.55 on December 19, 2025, amid heavy trading and technical breakout signals. The move follows recent investor conference appearances and ongoing focus on late-stage neuromuscular and cardiovascular drug programs. As of September 30, the company reported $563.3 million in cash and a Q3 net loss of $40.7 million.
20 December 2025
·
Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics shares jumped 8.79% to close at $23.01 on Dec. 19 after a volatile session and recent losses. The move coincided with elevated trading volume and options expiration. The company is advancing therapies for muscular dystrophies and cardiac conditions, with key clinical updates expected in late 2025 and beyond.
19 December 2025
···
Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics shares fell 8.8% to $20.35 on Thursday, with no new company news released that day. The stock traded between $20.33 and $22.81 on volume of about 1.25 million shares. EWTX remains 38% below its 52-week high and 92% above its 52-week low. The company’s recent updates include a December stock option grant and a November board appointment.
18 December 2025
··

Stock Market Today

  • Element Solutions Beats Q1 Earnings and Revenue Estimates on Strong Electronics Demand
    April 29, 2026, 10:01 AM EDT. Element Solutions Inc. (ESI) reported first-quarter 2026 earnings of 41 cents per share, excluding one-time items, beating the Zacks Consensus Estimate of 38 cents. Net sales rose 41% year over year to $840 million, surpassing the consensus of $744.4 million, driven by strong demand in its Electronics segment for AI infrastructure and high-performance electronics. The Electronics segment's organic net sales grew 15%, with adjusted EBITDA up 34%. However, net income fell 43% year on year to $56 million due to prior-year gains. ESI's cash decreased substantially, and debt rose to $2.06 billion. The company raised its full-year adjusted EBITDA outlook to $665 million-$685 million. Shares have surged 91.7% over the past year, outperforming the industry rise of 9.8%, while maintaining a Zacks Rank #3 (Hold).

Latest article

Lemonade Stock Jumps as Q1 Revenue Surge Sharpens Its 2026 Profit Test

Lemonade Stock Jumps as Q1 Revenue Surge Sharpens Its 2026 Profit Test

29 April 2026
Lemonade Inc reported first-quarter revenue of $258 million, up 71% from a year earlier, and narrowed its net loss to $35.8 million, or 47 cents a share. Shares rose 5.6% in premarket trading after results beat estimates. In-force premium climbed 32% to $1.33 billion, with customers up 23% to 3.14 million. The company raised its 2026 outlook and now expects full-year revenue of up to $1.203 billion.
Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

29 April 2026
Biogen lowered its 2026 adjusted earnings forecast to $14.25–$15.25 per share, citing research and development charges from recent acquisitions. First-quarter revenue rose 2% to $2.48 billion, with adjusted earnings of $3.57 per share, beating analyst estimates. Leqembi sales climbed 74% to $168 million globally.
Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Go toTop